Jove
Visualize
お問い合わせ

関連する概念動画

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

462
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
462
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

217
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
217
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The Development and Use of Office of New Drugs Custom Medical Queries for Safety Analyses of Clinical Trial Data.

Drug safety·2025
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Jan 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

規制上の意思決定における代理エンドポイント

Linda J B Jeng1, Jeffrey Siegel2

  • 1Division of Biomedical Informatics, Research, and Biomarker Development, Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.

Clinical and translational science
|December 19, 2025
PubMed
まとめ

FDAは、医薬品が患者の健康、機能、または生存を改善することを証明する強力なエビデンスを必要とします。代理エンドポイント(SE)として使用されるバイオマーカーは、アンメットニーズに対する新しい医薬品の開発をスピードアップできます。

キーワード:
バイオマーカー医薬品開発代理エンドポイント

さらに関連する動画

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays
08:00

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

7.9K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

関連する実験動画

Last Updated: Jan 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays
08:00

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

7.9K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

科学分野:

  • 薬理学
  • 臨床研究
  • バイオマーカー

背景:

  • 医薬品承認には有効性に関する実質的なエビデンスが必要です。
  • 有効性は、患者の気分、機能、または生存の改善を示す必要があります。
  • 臨床アウトカムは直接的または間接的に測定できます。

研究 の 目的:

  • FDAの医薬品有効性要件を説明すること。
  • 医薬品開発における代理エンドポイント(SE)の役割を強調すること。
  • SEとしてのバイオマーカーの可能性を強調すること。

主な方法:

  • FDAの有効性要件のレビュー。
  • 直接的および間接的なアウトカム測定の説明。
  • 代理エンドポイント(SE)およびバイオマーカーの議論。

主要な成果:

  • FDAは医薬品承認に実質的なエビデンスを義務付けています。
  • 有効性は、患者報告のアウトカムまたは代理エンドポイント(SE)を通じて評価されます。
  • バイオマーカーは効果的なSEとして機能することができます。

結論:

  • SEとしてのバイオマーカーは医薬品開発を加速できます。
  • これは、アンメットメディカルニーズのある状態にとって特に重要です。
  • SEとしてのバイオマーカーの利用は、FDAのエビデンス要件に沿っています。